Inventors are seeking licensing and/or co-development research collaborations for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.
The NIA seeks co-development partners and/or licensees for the further development of Cα-peptide as a therapeutic that inhibits islet amyloidosis.
The NICHD is seeking licensees for development of Carboxypeptidase E (CPE) as a therapy for MCI or AD.
NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.
NICHD is seeking licensees for development of an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.
NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.
Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.
Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells.
The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells.